1388858-78-3 Usage
Description
N-(4-isobutoxybenzyl)-N'-(4-fluorobenzyl)urea, also known as 1-[(4-Fluorophenyl)methyl]-3-[(4-isobutoxyphenyl)methyl]urea, is an organic compound with a urea functional group. It is characterized by its molecular structure that includes a benzyl group with an isobutoxy substituent and a fluorobenzyl group. N-(4-isobutoxybenzyl)-N'-(4-fluorobenzyl)urea is primarily recognized as an impurity in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
N-(4-isobutoxybenzyl)-N'-(4-fluorobenzyl)urea is used as an impurity in the synthesis and production of Pimavanserin (P441800), a drug utilized in the treatment of Parkinson's disease and psychosis. Its presence in the manufacturing process is crucial for ensuring the quality and safety of the final drug product, as it can impact the drug's efficacy and potential side effects.
As an impurity, N-(4-isobutoxybenzyl)-N'-(4-fluorobenzyl)urea is subject to strict regulatory controls and guidelines to maintain the overall quality and effectiveness of Pimavanserin. The compound's role in the pharmaceutical industry highlights the importance of understanding and managing impurities in drug development and production.
Check Digit Verification of cas no
The CAS Registry Mumber 1388858-78-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,8,8,5 and 8 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1388858-78:
(9*1)+(8*3)+(7*8)+(6*8)+(5*8)+(4*5)+(3*8)+(2*7)+(1*8)=243
243 % 10 = 3
So 1388858-78-3 is a valid CAS Registry Number.
1388858-78-3Relevant articles and documents
Tartaric acid pimavanserin impurities and preparation method thereof
-
, (2017/12/02)
The invention discloses tartaric acid pimavanserin impurities, namely N-(4-isobutoxy benzyl) diphenyl aminodiphthalate (impurity A), 4-isobutoxy benzyl carbonic acid phenyl ester (impurity B), 4-fluorobenzyl (1-methylpiperidine-4-yl) carbonic acid-4-isobutoxy benzyl ester (impurity C) and N-( isobutoxy benzyl)-N'-(4-fluorobenzyl) urea (impurity E). In addition, the invention further discloses a preparation method of tartaric acid pimavanserin impurities A, B, C and E and an N,N'-bis(4-isobutoxy benzyl) urea (impurity D). Through application of the tartaric acid pimavanserin impurities as reference substances in research on the quality of the tartaric acid pimavanserin intermediate, a crude drug and a compound preparation thereof, a solid foundation is laid for research on the quality of tartaric acid pimavanserin.
